Preliminary results of G>GVIELC:: A phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Santo, A.
Genestreti, G.
Azzoni, P.
Palmeri, S.
Caffo, O.
Cipriani, A.
Binato, E.
Cartei, G.
Portalone, L.
Sava, T.
Molino, A. M.
Cetto, G. L.
机构：
[1] Univ Verona, Verona Hosp, Dept Oncol, I-37100 Verona, Italy
[2] GIVOP, Verona, Italy
[3] Palermo Hosp, Oncol Unit, Palermo, Italy
[4] Trento Hosp, Oncol Unit, Trento, Italy
[5] Verona Hosp, Pneumol Unit, Verona, Italy
[6] Padova Hosp, Dept Oncol, Padua, Italy
[7] Forlanini Rome Hosp, Oncopneumol Unit, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI20 / XI20
页数：1
相关论文
共 50 条
  • [41] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [42] Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer
    Dómine, M
    Casado, V
    Estévez, LG
    León, A
    Martin, JI
    Castillo, M
    Rubio, G
    Lobo, F
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 4 - 9
  • [43] Gemcitabine and Cisplatin Followed by Concurrent Gemcitabine and Radiotherapy or Sequential Radiotherapy Alone in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
    Kerner, G. S. M. A.
    van Dullemen, L. F. A.
    Wiegman, E. M.
    van der Leest, A. H. D.
    Widder, J.
    Ubbels, J. F.
    Hiltermann, T. J. N.
    Groen, H. J. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S600 - S600
  • [44] Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer
    Hainsworth, JD
    Burris, HA
    Greco, FA
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 21 - 25
  • [45] Elderly patients with advanced non-small cell lung cancer - A phase II study with weekly cisplatin and gemcitabine
    Berardi, R
    Porfiri, E
    Scartozzi, M
    Lippe, P
    Silva, RR
    Nacciarriti, D
    Menichetti, ET
    Tummarello, D
    Carle, F
    Piga, A
    Cellerino, R
    ONCOLOGY, 2003, 65 (03) : 198 - 203
  • [46] A phase II study of gemcitabine (GEM) and vindesine (VDS) in unresectable non small cell lung cancer (NSLC) patients with advanced age or poor performance status: Preliminary data
    Santo, A
    Azzoni, P
    Durante, E
    Manno, P
    Oliani, C
    Burana, D
    Pasini, F
    Pedersini, R
    Cetto, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 11 - 11
  • [47] Gemcitabine (GEM) and carboplatin (CARB) in elderly patients with advanced non-small cell lung cancer (NSCLC): Subset analysis of a randomized phase II trial.
    Masters, GA
    Nickolov, A
    Hahn, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 679S - 679S
  • [48] Our experience of chemotherapy (CT) with gemcitabine alone and gemcitabine plus cisplatin for non-small cell lung cancer (NSCLC) patients (PTS)
    Marenich, A
    Gorbounova, V
    Reutova, E
    Breder, V
    Kozlov, D
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 257 - 260
  • [49] A phase I trial of paclitaxel, carboplatin, and gemcitabine in advanced non-small cell lung cancer
    Kelly, K
    Prindiville, S
    Bunn, PA
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 74
  • [50] Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial
    Masotti, A
    Zannini, G
    Gentile, A
    Morandini, G
    LUNG CANCER, 2002, 36 (01) : 99 - 103
12345